Loading...
•
Sep 30, 2024
Intensity Therapeutics Q3 2024 Earnings Report
Announced third quarter 2024 financial results and provided a corporate update.
Key Takeaways
Intensity Therapeutics reported a net loss of $3.5 million for the third quarter of 2024. The company's cash and cash equivalents totaled $2.8 million as of September 30, 2024, expected to fund operations into the first quarter of 2025. The first patient was dosed in randomized, Phase 2 study in presurgical triple negative breast cancer
First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer
INVINCIBLE-3 Study: first patients were dosed in the U.S.
INVINCIBLE-3 Study: authorization received from Health Canada to initiate the study in Canada, The European Medicines Agency to initiate the study in Europe, and Australia's Therapeutic Goods Administration to initiate study in Australia.
INVINCIBLE-4 Study: first patient dosed in the INVINCIBLE-4 Study.
Intensity Therapeutics
Intensity Therapeutics
Forward Guidance
The Company expects that cash and cash equivalents will be sufficient to fund operations into the first quarter in 2025.